Fig. 3
From: A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
Activation marker upregulation and increased phosphorylation of ERK protein by TIGIT-28 transduced T-lymphocytes. a-c Transduced PBLs with either TIGIT-28-F4 or Ctrl-F4 cells were co-cultured with melanoma lines (as indicated on the left side) and analyzed by flow cytometry for activation marker expression (CD25 (a), 4-1BB/CD137 (b) and CD69 (c)) gated on the CD8+ population (as indicated). The percentage of positive cells and the MFI (in brackets) are shown. These results are representative of at least three independent experiments (summary results shown in the right panels) with at least three donors and the difference between TIGIT-28 and the control was found to be statistically significant (*:p < 0.05, calculated using a Student’s paired t-test). d-e Transduced PBLs with either TIGIT-28-F4 or TCR F4 only (control) cells were incubated with 888A2/155 melanoma line for 30 min. (for pERK- in 5D) or overnight (for Bcl-xL – in 5E) and analyzed for intracellular levels of these proteins. These results are representative of three independent experiments (summary results shown in the right panels) and the difference between the two groups was found statistically significant (p < 0.04, calculated using a Student’s paired t-test)